Tango Therapeutics and Revolution Medicines reported that combining Tango’s vopimetostat with Revolution’s daraxonrasib produced durable responses in a small pancreatic cancer clinical study, according to Tango’s update. Industry coverage highlighted the result as an outlier for response durability in the disease, where new treatment options remain limited. Separately, Tango indicated it plans to initiate a phase 3 pancreatic cancer trial after the combination’s success. The development follows Revolution’s recent clinical spotlight at major oncology meetings. Together, the filings and follow-on plan point to a potential pivot in pancreatic cancer combination strategy and set up a longer confirmatory phase for the regimen.